|Day Low/High||1.63 / 1.68|
|52 Wk Low/High||1.46 / 7.85|
Piclidenoson is being developed as a first line therapy and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for rheumatoid arthritis
- Board members are Key Opinion Leaders in the field of liver diseases
- Data show Namodenoson both prevents and inhibits liver fibrosis
- $35 Billion treatment market by 2025 with need for an FDA approved drug
- Phase II trial to treat NAFLD/NASH expected to commence in 2017
-- Patient enrollment to commence Q2 2017
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKD, CCE, CFBK, FIT Downgrades: FWRD, SIG, VIA Initiations: CANF Read on to get TheStreet Quant Ratings' detailed report:
Can-Fite BioPharma (CANF) stock is gaining on Monday afternoon as the company announced pre-clinical data for CF602, which demonstrated statistically significant full recovery from erectile dysfunction after a single dose.
Can-Fite BioPharma (CANF) shares are down over 10% after pricing its secondary registered direct offering of 1.1 million shares.
These stocks trading for under $10 a share look ready to break out and trade higher from current levels.
Can-Fite (CANF) shares are up after the company's liver cancer treatment candidate was granted fast track designation by the FDA.
Can-Fite BioPharma (CANF) shares are up over 40% after its liver cancer treatment candidate received FDA fast track designation.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Shares of Can-Fite BioPharma (CANF) plunged to a one-year low on Monday announced that its drug candidate CF101 did not achieve its primary endpoint in a Phase II/III psoriasis trial.
TheStreet highlights 3 stocks that pushed the Drugs industry
TheStreet highlights 3 stocks pushing the Health Care sector lower today.